On December 31st, 2019, the World Health Organization (WHO) was informed of several cases of severe pneumonia in the Chinese metropolis of Wuhan City, caused by a previously unknown virus. On January 7th, 2020 the Chinese authorities announced that they had identified the new virus - temporarily named “2019-nCoV” - belonging to the coronavirus family.
The number of cases of 2019-nCoV infections in China is rising dramatically and cases in other Asian countries as well as in the USA were confirmed. Therefore, reliable diagnoses on a large scale are increasingly needed, even outside China.
altona Diagnostics is in the process of developing a molecular diagnostic assay for the detection of the new coronavirus 2019-nCoV, in close cooperation with major reference institutes for emerging diseases. The company is putting big efforts in this project to make a reliable test commercially available to customers as soon as possible. The scientists can draw on the experience of previous product developments for the detection of other emerging viruses. altona Diagnostics was one of the first companies to make reliable molecular diagnostic kits commercially available during outbreak situations for SARS-CoV, MERS-CoV, Ebolavirus and Zika virus, among others.
The real-time RT-PCR based assay currently under development will be designed for the qualitative detection of 2019-nCoV specific RNA in respiratory samples.
More News
Grand opening of new altona Diagnostics production site
In the fall of 2024, altona celebrated the grand opening of its new extraction chemistry production site located at Schnackenburgallee in Hamburg opposite the premises ...
Read more …New management at altona Diagnostics in Argentina and Brazil
After more than six years at the helm of the Argentine and Brazilian subsidiaries of altona Diagnostics based in Buenos ...
Read more …altona Diagnostics on course for growth
The fact that the pandemic has also given a boost to certain sectors of the economy is particularly noticeable at a company like
Read more …